Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Solvonis Therapeutics CEO on 'transformative' Awakn acquisition and Phase 3 progress

5:07
 
Share
 

Manage episode 485460612 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Solvonis Therapeutics PLC CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the completion of the company’s acquisition of Awakn Life Sciences and the progress of its lead clinical program. Tennyson explained that the acquisition positions Solvonis as a biotechnology firm focused on treating addiction and mental health disorders. A key asset from the deal, formerly AWKN-001 and now renamed SVN-001, targets severe alcohol use disorder and is currently in a Phase 3 clinical trial. "The results of the phase two for that program were groundbreaking," Tennyson said, highlighting that participants improved from 2% sobriety to 86% six months post-treatment. The Phase 3 trial is being conducted in partnership with the UK Department of Health at an unusually low cost of £800,000 – a figure Tennyson noted is “unheard of really, in the biopharmaceutical industry.” The trial is being carried out within the NHS and supported by UK addiction specialists and the Department of Health and Social Care, adding national relevance to the program. Tennyson also discussed a second program, SVN-002, focused on alcohol use disorder in the U.S., and outlined plans to integrate Awakn’s assets and grow Solvonis’s team. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel and enable notifications for future content. #SolvonisTherapeutics #AlcoholAddictionTreatment #SVN001 #BiotechNews #Phase3Trial #MentalHealthInnovation #AwaknAcquisition #ClinicalResearch #AddictionRecovery #ProactiveInvestors
  continue reading

605 episodes

Artwork
iconShare
 
Manage episode 485460612 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Solvonis Therapeutics PLC CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the completion of the company’s acquisition of Awakn Life Sciences and the progress of its lead clinical program. Tennyson explained that the acquisition positions Solvonis as a biotechnology firm focused on treating addiction and mental health disorders. A key asset from the deal, formerly AWKN-001 and now renamed SVN-001, targets severe alcohol use disorder and is currently in a Phase 3 clinical trial. "The results of the phase two for that program were groundbreaking," Tennyson said, highlighting that participants improved from 2% sobriety to 86% six months post-treatment. The Phase 3 trial is being conducted in partnership with the UK Department of Health at an unusually low cost of £800,000 – a figure Tennyson noted is “unheard of really, in the biopharmaceutical industry.” The trial is being carried out within the NHS and supported by UK addiction specialists and the Department of Health and Social Care, adding national relevance to the program. Tennyson also discussed a second program, SVN-002, focused on alcohol use disorder in the U.S., and outlined plans to integrate Awakn’s assets and grow Solvonis’s team. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel and enable notifications for future content. #SolvonisTherapeutics #AlcoholAddictionTreatment #SVN001 #BiotechNews #Phase3Trial #MentalHealthInnovation #AwaknAcquisition #ClinicalResearch #AddictionRecovery #ProactiveInvestors
  continue reading

605 episodes

Alle episoder

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play